Anika Therapeutics | ANIK - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Abbott USD 42M 2M 2025-12
Agenus USD 16.02M 2.85M 2025-12
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.6M 217K 2025-12
Integra LifeSciences USD 23.67M 953K 2025-12
Intrexon USD 2K 5K 2024-06
J&J USD 18M 290M 2025-09
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
Ligand Pharmaceuticals USD 910K 243K 2025-09
MacroGenics USD 3.34M 2.54M 2025-09
Merit Medical Systems USD 6.36M 390K 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 252M 2025-12
Smith & Nephew USD 69M 1000K 2025-12
Stryker USD 157M 46.17B 2025-09
Surmodics USD 884K 5K 2024-09
Veracyte USD 2K 1000 2023-12
Xencor USD 7.35M 311K 2025-12
Zimmer Biomet Holdings USD 71.9M 3.5M 2025-12